Our team recently contributed to advances in care in two important areas of neurology.
As treatment options start to become available for Alzheimer’s disease (AD), it’s becoming increasingly important to correctly diagnose patients and diagnose them early. Accurate biomarker testing is required together with imaging and neuropsychiatric testing to assess for cognitive impairment.
Fujirebio engaged us to help educate pathologists and neurologists on the importance of AD diagnosis and the current and emerging diagnostic options. This initiative involved development of an unbranded comprehensive slide library that was used as a foundation to educate internal and external audiences including a webinar targeting neurologists and pathologists CSF Biomarkers: Aid in the differential diagnosis of Alzheimer’s disease and an article in CAP Today CSF Biomarkers in a ‘new era’ of Alzheimer’s.
Anti-calcitonin gene-related peptide (CGRP) represents a new and effective treatment option for people suffering with migraine headaches. In collaboration with opinion leaders and the medical affairs team at Alder BioPharmaceuticals, Medical Minds developed an educational initiative to educate headache specialists and other neurologists about the advantages of eptinezumab, an anti-CGRP, delivered via quarterly IV infusion. View case study.